PTPRJ-Targeting Peptide Agonist Induces Broad Cellular Signaling Perturbations and DNA Damage in Lung Cancer Cells
Authors:
- Sophie RizzoSRSophie Rizzo
- William S. HartWHWilliam S. Hart
- Rachel L. FetterRFRachel L. Fetter
- Bokai SongBSBokai Song
- Forest M. WhiteFWForest M. White
- Matthew J. LazzaraMLMatthew J. Lazzara
- Damien ThéveninDTDamien Thévenin
Preprint
Abstract
Receptor protein tyrosine phosphatases (RPTPs) are key regulators of cell signaling. However, their study and therapeutic targeting have been limited by the lack of known natural ligands or selective agonists, as well as an incomplete understanding of their structure-function relationships. Nonetheless, receptor homodimerization has been shown to suppress RPTP catalytic activity by restricting substrate access, offering a promising strategy for examining and modulating their function. Our previous work on PTPRJ, a member of the RPTP family, showed that its transmembrane domain regulates homodimerization, thereby controlling access to receptor tyrosine kinase (RTK) substrates and their phosphorylation levels. We also developed peptides that disrupt this dimerization, thereby inhibiting RTK phosphorylation and reducing cancer cell migration. These peptides were then engineered for selective, pH-sensitive insertion into the acidic tumor microenvironment to enhance efficacy while limiting off-target effects. Yet how broadly PTPRJ activation reshapes the phosphotyrosine landscape and whether those changes yield coherent cellular phenotypes remains unclear. In this study, we employed tyrosine phosphoproteomics, immunoblotting, immunofluorescence, and functional assays to assess the global impact of our lead peptide candidate, Hybrid 7, in A549 lung cancer cells that endogenously express PTPRJ. We find that Hybrid 7 decreases EGFR phosphorylation and selectively reduces phosphorylation across additional RTKs and motility adaptors, producing strong inhibition of EGF-driven migration and reduced proliferation. Hybrid 7 also elevates reactive oxygen species and DNA damage, and enforces CDK1-dependent G2/M arrest, indicating a primarily cytostatic, checkpoint-mediated response. These findings highlight the potential of RPTP-targeting peptides as valuable tools for dissecting RPTP function and as possible therapeutic agents capable of modulating key oncogenic pathways and inhibiting cancer progression.Keywords
Funding Information
- National Institutes of Health (R01GM139998)
- National Institutes of Health (P30CA044579)
- National Institutes of Health (U54CA283114)
This publication has 105 references indexed in Scilit:
- Promoting the activity of a receptor tyrosine phosphatase with a novel pH‐responsive transmembrane agonist inhibits cancer‐associated phenotypesProtein Science, 2023
- LKB1 loss is associated with glutathione deficiency under oxidative stress and sensitivity of cancer cells to cytotoxic drugs and γ-irradiationBiochemical Pharmacology, 2018
- The G2 checkpoint—a node‐based molecular switchFEBS Open Bio, 2017
- Detection and Identification of Ligands for Mammalian RPTP Extracellular Domains2016
- Dragging Ras Back in the RingCancer Cell, 2014
- Protein tyrosine phosphatases as novel targets in breast cancer therapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2013
- Distinct Activation of Epidermal Growth Factor Receptor by UTP Contributes to Epithelial Cell Wound RepairThe American Journal of Pathology, 2011
- Aurora‐A expressing tumour cells are deficient for homology‐directed DNA double strand‐break repair and sensitive to PARP inhibitionEMBO Molecular Medicine, 2010
- EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with AktCancer Cell, 2009
- A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transductionCell, 1992